Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill could stop and treat dangerous swelling attacks

NCT ID NCT07266805

Disease control Sponsor: Pharvaris Netherlands B.V. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 30, 2026 · Updated 2 times

Summary

This Phase 3 trial tests an oral drug called deucrictibant in adults with acquired angioedema due to C1 inhibitor deficiency, a rare condition causing sudden, painful swelling attacks. The study has three parts: one to see if a daily extended-release tablet can prevent attacks, another to test an immediate-release capsule for on-demand treatment, and an open-label part for long-term safety. About 32 participants will be enrolled to compare the drug against placebo.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Deucrictibant
What this could lead to
If successful, this could provide a new oral option to prevent and treat swelling attacks in people with acquired angioedema, reducing the need for emergency care.
What could go wrong
This is a small Phase 3 trial with only 32 participants, so results may not apply to everyone. The drug may not work better than placebo, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 32 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2025

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Provision of written informed consent * Male or female (sex at birth) aged ≥18 years * Diagnosis of AAE-C1INH * History of AAE-C1INH attacks prior to the Screening Visit: * Participants enrolling in Part 1 must have stable underlying disease of AAE-C1INH * The underlying condition can reasonably be expected to remain stable for the duration * Reliable access and ability to use available therapy to effectively manage AAE- C1INH attacks. * Female participants of childbearing potential must agree to the protocol-specified pregnancy testing and to be abstinent from heterosexual intercourse or to use an acceptable contraception method. Females of non-childbearing potential (prepubertal, surgically sterile, or postmenopausal with ≥ 12 months amenorrhea and postmenopausal FSH confirmation) are not required to use contraception during the study. • Capable of recording, without assistance, eDiary and ePRO data using an electronic device, as evidenced by the eDiary and ePRO training. Exclusion Criteria: * Participation in a clinical study with any other investigational drug within the last 30 days or within 5 half-lives of the investigational drug at the Screening Visit (whichever is longer). * Participants who have previously received prophylactic therapy but have stopped can participate in this study provided the last dose of the treatment was received prior to the timepoint before the Screening Visit * Any females who are pregnant, plan to become pregnant, or are currently breast-feeding * Abnormal hepatic function * Moderate or severe renal impairment * Any clinically significant comorbidity or systemic dysfunction that would interfere with the participant's safety or ability to participate in the study. * History of epilepsy and/or other significant neurological diseases * Any clinically significant and uncontrolled gastrointestinal dysfunction that may impact study drug absorption * Evidence of current alcohol or drug abuse * Use of medications that are moderate and strong inhibitors of cytochrome P450 (CYP) 3A4, or strong inducers of CYP3A4 within the last 30 days or within 5 half-lives (whichever is longer) at the time of the Screening Visit * Known hypersensitivity to deucrictibant or any of the excipients of the study drug * Use of angiotensin-converting enzyme inhibitors or any estrogen-containing medications

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acquired angioedema due to C1-inhibitor deficiency (aae-C1-inh) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acquired angioedema acquired angioedema with C1Inh deficiency angioedema hereditary angioedema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acquired angioedema due to C1-inhibitor deficiency (aae-C1-inh)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    32 sites in 16 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Study Site

    RECRUITING

    San Diego, California, 92093, United States

  • Study Site

    RECRUITING

    Walnut Creek, California, 94598,, United States

  • Study Site

    RECRUITING

    St Louis, Missouri, 63130, United States

  • Study Site

    RECRUITING

    Hershey, Pennsylvania, 17033, United States

  • Study Site

    RECRUITING

    Clayton, Australia

  • Study Site

    RECRUITING

    Vienna, Austria

  • Study Site

    RECRUITING

    Sofia, Bulgaria

  • Study Site

    RECRUITING

    Edmonton, Canada

  • Study Site

    RECRUITING

    Grenoble, France

  • Study Site

    RECRUITING

    Lille, France

  • Study Site

    RECRUITING

    Paris, France

  • Study Site

    RECRUITING

    Berlin, Germany

  • Study Site

    RECRUITING

    Frankfurt am Main, Germany

  • Study Site

    RECRUITING

    Munich, Germany

  • Study Site

    RECRUITING

    Budapest, Hungary

  • Study Site

    RECRUITING

    Padova, Italy

  • Study Site

    RECRUITING

    Roma, Italy

  • Study Site

    RECRUITING

    Amsterdam, Netherlands

  • Study Site

    RECRUITING

    Auckland, New Zealand

  • Study Site

    RECRUITING

    Krakow, Poland

  • Study Site

    RECRUITING

    Madrid, Spain

  • Study Site

    RECRUITING

    Basel, Switzerland

  • Study Site

    RECRUITING

    Ankara, Turkey (Türkiye)

  • Study Site

    RECRUITING

    Bristol, United Kingdom

  • Study Site

    RECRUITING

    Cambridge, United Kingdom

  • Study Site

    RECRUITING

    Leicester, United Kingdom

  • Study Site

    RECRUITING

    London, United Kingdom

  • Study Site

    RECRUITING

    Newcastle upon Tyne, United Kingdom

  • Study Site

    RECRUITING

    Plymouth, United Kingdom

  • Study Site 1

    RECRUITING

    Milan, Italy

  • Study Site 2

    RECRUITING

    Milan, Italy

  • Study Site 3

    RECRUITING

    Milan, Italy